Celularity Inc. Class A Common Stock (CELU)

About CELU

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therap…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

115

Website

www.celularity.com

Fundamentals

1-day range

$0.926$2.54

Market cap

$19.11M

P/E (trailing)

—

P/E (forward)

-3.70

EPS (trailing)

$-3.59

Dividend yield

—

Beta

0.54

Avg. volume

118.5K

Celularity Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• CELU

  Celularity Inc. Class A Common Stock

  $1.57

  ▼ 25.24%
  Market cap $19.11MP/E —
  $0.56$4
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.17MP/E —
  $0.72$3.78
• ALLR

  Allarity Therapeutics Inc. Common Stock

  $1.41

  ▲ 2.17%
  Market cap $19.64MP/E —
  $0.769$2.06
• NCEL

  NewcelX Ltd. Ordinary Shares

  $3.19

  ▼ 6.73%
  Market cap $18.41MP/E —
  $1.83$24.6
• PLRZ

  Polyrizon Ltd. Ordinary Shares

  $12.7

  ▼ 0.78%
  Market cap $19.82MP/E —
  $2.88$18.2
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $20.34MP/E —
  $0.8099$2.46
• SKYE

  Skye Bioscience Inc. Common Stock

  $1.81

  ▼ 7.18%
  Market cap $20.53MP/E —
  $1.84$39.92

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

2.09M

Total value held

$2.76M

Institutional holders

35